Insight Molecular Diagnostics: $2B Market for GraftAssureDx Insight Molecular Diagnostics projects a $2.0B annual addressable market for GraftAssureDx (Seeking Alpha, Mar 27, 2026) and signals a rapid commercialization push.

Insight Molecular Diagnostics: $2B Market for GraftAssureDx: Insight Molecular Diagnostics projects a $2.0B annual addressable market for GraftAssureDx (Seeking Alpha, Mar 27, 2026) and… 👈 Read full analysis #MolecularDiagnostics #HealthcareInnovation #GraftAssureDx #MarketResearch #Biotechnology

#OncocyteCorp #OCX announced a higher CMS reimbursement rate of $2,753 for its GraftAssureCore transplant rejection test. This update strengthens its position in the $1B transplant diagnostics market...
#OncocyteCorp #GraftAssureDx
prismmarketview.com/oncocyte-sec...